Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth

Company Overview - Bausch Health (BHC) is expected to report a year-over-year increase in earnings, with a projected EPS of $1.44, reflecting a change of +144.1% [3] - Revenues are anticipated to reach $2.27 billion, marking a 5.5% increase from the previous year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 3.44% over the last 30 days, indicating a bearish sentiment among analysts [4] - The Most Accurate Estimate for Bausch is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -35.93%, which complicates the prediction of an earnings beat [10][11] Historical Performance - In the last reported quarter, Bausch exceeded the consensus EPS estimate of $1.12 by delivering earnings of $1.15, resulting in a surprise of +2.68% [12] - Over the past four quarters, Bausch has beaten consensus EPS estimates two times [13] Market Sentiment - The stock's movement is contingent on the upcoming earnings report, with potential for an increase if results exceed expectations, while a miss could lead to a decline [2] - Despite the negative Earnings ESP, the stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [11] Industry Context - BridgeBio Pharma (BBIO), a peer in the Zacks Medical - Generic Drugs industry, is expected to report a significant decline in earnings, with an EPS estimate of $0.91, reflecting a year-over-year change of -1,720% [17] - BridgeBio's revenues are projected to be $62.45 million, down 70.4% from the previous year [17] - The consensus EPS estimate for BridgeBio has been revised down by 1.8% over the last 30 days, but a higher Most Accurate Estimate has resulted in a positive Earnings ESP of 0.24% [18]